Jacqueline G O'Leary1, Göran B Klintmalm. 1. Annette C. & Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas 75246, USA. Jacquelo@BaylorHealth.edu
Abstract
PURPOSE OF REVIEW: To critically examine the recent literature evaluating the importance of HLA donor-specific antibody (DSA) impact on liver transplant and simultaneous liver-kidney transplant (SLKT) outcomes. RECENT FINDINGS: Many preformed DSAs, especially of low mean fluorescence intensity (MFI), are absorbed by the liver at transplant. However, patients with post-liver transplant DSA, especially of higher MFI, are at increased risk of acute and chronic rejection. C4d staining, when positive, may be helpful but lacks sensitivity especially in formalin tissue. SLKT recipients may need close follow-up when class II DSA is found, as the liver protects the kidney from hyperacute rejection, but can still cause early renal antibody-mediated rejection, liver allograft rejection, and impair patient, liver allograft, and renal allograft survival. SUMMARY: Some DSAs are relevant in liver transplant and can lead to acute and chronic allograft rejection. However, before clinical practice patterns can change we must create unified diagnostic criteria, define the pathologic potential of different DSAs, and improve the specificity of current testing.
PURPOSE OF REVIEW: To critically examine the recent literature evaluating the importance of HLA donor-specific antibody (DSA) impact on liver transplant and simultaneous liver-kidney transplant (SLKT) outcomes. RECENT FINDINGS: Many preformed DSAs, especially of low mean fluorescence intensity (MFI), are absorbed by the liver at transplant. However, patients with post-liver transplant DSA, especially of higher MFI, are at increased risk of acute and chronic rejection. C4d staining, when positive, may be helpful but lacks sensitivity especially in formalin tissue. SLKT recipients may need close follow-up when class II DSA is found, as the liver protects the kidney from hyperacute rejection, but can still cause early renal antibody-mediated rejection, liver allograft rejection, and impair patient, liver allograft, and renal allograft survival. SUMMARY: Some DSAs are relevant in liver transplant and can lead to acute and chronic allograft rejection. However, before clinical practice patterns can change we must create unified diagnostic criteria, define the pathologic potential of different DSAs, and improve the specificity of current testing.
Authors: Jacqueline G O'Leary; Hugo Kaneku; Anthony J Demetris; John D Marr; S Michelle Shiller; Brian M Susskind; Glenn W Tillery; Paul I Terasaki; Göran B Klintmalm Journal: Liver Transpl Date: 2014-01-02 Impact factor: 5.799
Authors: Jacqueline G O'Leary; S Michelle Shiller; Christopher Bellamy; Michael A Nalesnik; Hugo Kaneku; Linda W Jennings; Kumiko Isse; Paul I Terasaki; Göran B Klintmalm; Anthony J Demetris Journal: Liver Transpl Date: 2014-10 Impact factor: 5.799
Authors: Jaap Kwekkeboom; Nicolle H R Litjens; Aafke A Duizendstra; Robert J de Knegt; Shanta Mancham; Mariska Klepper; Dave L Roelen; Simone H Brand-Schaaf; Patrick P Boor; Michail Doukas; Robert A de Man; Dave Sprengers; Maikel P Peppelenbosch; Michiel G H Betjes Journal: Liver Transpl Date: 2021-07-21 Impact factor: 6.112
Authors: Seung Hwan Song; Myoung Soo Kim; Jung Jun Lee; Man Ki Ju; Jae Geun Lee; Juhan Lee; Jin Sub Choi; Gi Hong Choi; Soon Il Kim; Dong Jin Joo Journal: Ann Surg Treat Res Date: 2015-01-27 Impact factor: 1.859
Authors: Safak Gül-Klein; Henriette Hegermann; Robert Röhle; Moritz Schmelzle; Frank Tacke; Wenzel Schöning; Robert Öllinger; Tomasz Dziodzio; Patrick Maier; Julius M Plewe; David Horst; Igor Maximilian Sauer; Johann Pratschke; Nils Lachmann; Dennis Eurich Journal: J Inflamm Res Date: 2021-06-23